BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
ROCHESTER, NY / ACCESSWIRE / February 10, 2016 / As the Summer Olympics, taking place in Rio de Janeiro, Brazil, are fast approaching, concerns over the Zika virus are mounting. Very little is known about the virus and scientists are working hard to find a treatment. Currently no drug is available to combat Zika, so researchers are focusing on other methods of prevention and early detection.
PositiveID Corporation (PSID) is at the forefront of developing a unique bio detection device, its Firefly Dx handheld diagnostic system, which can be used in the field to identify threats such as Zika, dengue fever, SARS, Ebola, influenza, agricultural disease, etc., at the point of need. Also, with the recent acquisition of two established, revenue generating businesses, E-N-G Mobile Systems, Inc. and Thermomedics, Inc., PSID is poised to dominate this niche of the biotech realm.
PSID developed its M-BAND product, with over $30 million of contract funding from the Department of Homeland Security, to autonomously and continuously analyze the air for weaponized pathogens such as Anthrax and other biological threats in real time, wirelessly with all programmed field instruments.
The Firefly Dx product in development at the PSID labs could be the perfect solution for battling the Zika virus. As there is not yet a prevention drug or vaccine, early detection is imperative to containing this deadly virus. PSID's handheld mobile device, the Firefly Dx, is designed to analyze and detect a wide array of pathogens on an as needed basis in less than 30 minutes out in the field - essentially condensing a whole laboratory into the palm of your hand. This compares to the current lab-based testing, which requires equipment far larger, far slower and far more costly. This exciting new adaptable device could be a revolutionary component in the battle against Zika and any future threats.
In other biotech news:
Xencor, Inc. (NASDAQ: XNCR) announced they will presenting at two upcoming conferences in New York City in February: the Leerink Partners 5th Annual Global Healthcare today, and the 2016 RBC Capital Markets Healthcare Conference on Wednesday, February 24th, at 4:35 pm. Xencor is a biopharmeuctical company that currently has two monoclonal antibodies engineered to treat asthma, autoimmune diseases, allergic diseases and cancer.
Pioneers of the humanization of monoclonal antibodies PDL BioPharma Inc. (NASDAQ: PDLI) presented Monday, live via web cast, available here http://www.pdl.com. Its CEO and president John P. McLaughlin will be at the BIO CEO and Investor Conference.
Another presenter at the conference Monday was will be Trevena Inc. (NASDAQ: TRVN), whose presentation is available at www.trevenainc.com TRVN is in the initial stages of developing biased ligands that target G protein receptors that aid with moderate to severe pain, treat acute heart failure, treat moderate to severe acute and chronic pain orally, and for acute episodic migraine and central nervous disorders.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechMarketReport.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechMarketReport.com's parent company, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechMarketReport.com's parent company, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. BiotechMarketReport.com's parent company has been compensated a total of $1,500 cash by A non-affiliate third party of PSID.
SOURCE: BiotechMarketReport.com
